CENIX BIOSCIENCE Announces Collaboration with Bayer HealthCare AG to Discover and Validate Novel Therapeutic Targets
"Having launched these HT-RNAi research offerings only this summer after years of careful R&D, we have been particularly gratified by the overwhelming market interest, of which this agreement represents a first, important milestone" said Dr Echeverri, CEO and CSO of Cenix BioScience GmbH.
The project will make use of the genome-wide library of siRNA molecules designed by Cenix using its industry-leading algorithms and produced by Ambion, Inc. (Austin, TX, USA). Under the deal, Cenix will receive upfront payments and research funding, and is eligible for downstream milestone payments. Bayer will have the option to obtain all rights to new intellectual property generated by the project.
Topics
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.